Back
Immunovant, Inc. (IMVT)
BiotechnologyIMVT · NASDAQ NMS - GLOBAL MARKET · USD
New to investing? How to read this page →$39.68
−3.41%Price · 1 year
Loading live analysis…
Loading analysis…
Intrinsic Investor is for education and research only — not financial advice.
Key metrics
EPS
$-2.77
ROE
-64.8%
Gross margin
0.0%
Debt/Equity
0.01x
Revenue growth
P/B ratio
Beta
Forward P/E
Immunovant, Inc. — company intelligence
Earnings surprises
Q4 2026$-0.73 vs $-0.61 est-19.1%
Q3 2026$-0.61 vs $-0.73 est+16.3%
Q2 2026$-0.73 vs $-0.73 est+0.2%
Q1 2026$-0.71 vs $-0.66 est-8.0%
Analyst consensus · 24 analysts
18 Buy6 Hold0 Sell
Updated Jul 6, 2026
Insider activity · 90 days
0 buys15 sellsnet -334,254 shares
Van Tuyl Christopherother 17,824 · Jun 26, 2026
Girao Tiagoother 10,000 · Jun 26, 2026
Gloria MelanieSell 2,966 · Jun 26, 2026
Recent SEC filings
4 — Insider transaction reportJun 26, 2026
4 — Insider transaction reportJun 26, 2026
4 — Insider transaction reportJun 26, 2026
Latest news
Citigroup Maintains Buy on Immunovant, Raises Price Target to $61 — Benzinga · 1w ago
AI Valuation Narrative
Generates a short bull / bear / catalyst summary from the analytics we already computed. No target prices. Research tool, not investment advice.
Explore more
Peers & similar stocks
Quick links to related tickers for research.
About Immunovant, Inc.
Weekly undervalued picks (like IMVT)
Get 3 new value ideas and the fair-value math behind them every week. One email, unsubscribe anytime.
Free. No spam. We only email once per week.
Data is provided "as-is" and may be delayed or incomplete. Intrinsic Investor is for education only and is not investment advice.